Your browser doesn't support javascript.
loading
Therapy for Gaucher disease: don't stop thinking about tomorrow.
Sidransky, Ellen; LaMarca, Mary E; Ginns, Edward I.
Afiliación
  • Sidransky E; Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, NIH, Building 35, Room 1A213, 35 Convent Drive, MSC 3708, Bethesda, MD 20892, USA. sidranse@mail.nih.gov
Mol Genet Metab ; 90(2): 122-5, 2007 Feb.
Article en En | MEDLINE | ID: mdl-17084653
ABSTRACT
While enzyme replacement therapy for Gaucher disease has been widely used and appears to be an efficacious and safe treatment, this success should not be a reason for complacency. Other treatment strategies currently under consideration for patients with Gaucher disease include gene therapy, substrate reduction therapy and chaperone therapy. Furthermore, improvements in enzyme therapy could also have a significant clinical impact. Individuals with Gaucher disease and other lysosomal disorders will greatly benefit from continual refinement and optimization of the current therapy, as well as from the development of new treatment modalities that offer improvements in efficacy, cost, safety and availability.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Gaucher Límite: Humans Idioma: En Revista: Mol Genet Metab Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Año: 2007 Tipo del documento: Article País de afiliación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Gaucher Límite: Humans Idioma: En Revista: Mol Genet Metab Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Año: 2007 Tipo del documento: Article País de afiliación: Estados Unidos